Novo nordisk and life edit therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases

Life edit will receive an upfront cash payment and is eligible to receive milestone payments of 250- 335 million us dollars for each of seven development programmes , as well as tiered royalties on global net sales .

NVO Ratings Summary

NVO Quant Ranking